Repligen Corp
RGEN: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|>! | LOCK|p$<c | LOCK|Yz$h&h> |
Repligen Earnings: Double-Digit Revenue Growth and Margin Improvement To Continue in 2026
Repligen reported year-on-year revenue growth of 14% for the quarter and 16% for the year. Full-year adjusted EBITDA margin was 19%, or 50 basis points better than last year. Management's guidance for 2026 includes 9% to 13% organic revenue growth and adjusted EBITDA margin of 20.0% to 20.5%.
